Volume 14, Number 11—November 2008
Research
Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus, Rural Southwestern Alaska1
Table 2
Characteristic | No. (%) |
---|---|
Sex | |
Male | 61 (50.8) |
Female | 56 (46.7) |
Unknown |
3 (2.5) |
Age, y | |
>1–2 | 11 (9.2) |
3–12 | 14 (11.7) |
13–20 | 22 (18.3) |
21–49 | 53 (44.2) |
>50 | 18 (15.0) |
Unknown |
2 (0.2) |
Location of care | |
Inpatient | 11 (9.2) |
Outpatient | 106 (88.4) |
Emergency department | 59 (49.2) |
Other outpatient | 47 (39.2) |
Unknown |
3 (2.5) |
Place of onset by 72-h rule† | |
Community | 114 (95.0) |
Hospital | 1 (0.8) |
Unknown |
5 (3.3) |
Site of isolation | |
Blood | 3 (2.5) |
Respiratory tract | 1 (0.8) |
Skin/wound | 108 (90.0) |
Urine | 2 (1.7) |
Bone/joint | 1 (0.8) |
Other | 5 (4.2) |
*MRSA, methicillin-resistant Staphylococcus aureus.
†MRSA isolates were considered community onset if they were obtained from a patient in the outpatient setting or from a hospitalized patient within 72 h of admission; only 1 isolate was obtained from a patient who was considered to have had onset of the infection in the hospital.
1Portions of this study were presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17–20, 2007, Chicago, IL, USA.
Page created: July 18, 2010
Page updated: July 18, 2010
Page reviewed: July 18, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.